Jawed Fareed, PhD

Pathology

Molecular Pharmacology and Therapeutics
Professor

Languages Spoken

English

Research

  • Antithrombotic therapy in 2014: Making headway in anticoagulant and antiplatelet therapy Fareed, J., Nature reviews.Cardiology
  • Characterization of the Antithrombotic Fingerprint of the Branded and Copies of the Low-Molecular-Weight Enoxaparin Using Thrombin Generation Assay Gerotziafas, G. T.; Rouseau, A.; Mbemba, E.; Khartechi, A.; Dreden, P. V.; Walenga, J.; Fareed, J.; Elalamy, I., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • d-Dimer Levels are Significantly Increased in Blood Taken From Varicose Veins Compared With Antecubital Blood From the Same Patient Lattimer, C. R.; Kalodiki, E.; Geroulakos, G.; Syed, D.; Hoppensteadt, D.; Fareed, J., Angiology
View All ResearchShow Less
  • Differentiation of Generic Enoxaparins Marketed in the United States by Employing NMR and Multivariate Analysis Guerrini, M.; Rudd, T. R.; Mauri, L.; Macchi, E.; Fareed, J.; Yates, E. A.; Naggi, A.; Torri, G., Analytical Chemistry
  • Do Blood Constituents in Varicose Veins Differ From the Systemic Blood Constituents? Poredos, P.; Spirkoska, A.; Rucigaj, T.; Fareed, J.; Jezovnik, M. K., European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
  • Does escitalopram reduce neurotoxicity in major depression? Halaris, A.; Myint, A. M.; Savant, V.; Meresh, E.; Lim, E.; Guillemin, G.; Hoppensteadt, D.; Fareed, J.; Sinacore, J., Journal of psychiatric research
  • Elevated endocan levels and its association with clinical severity in Stevens-Johnson Syndrome and toxic epidermal necrolysis Syed, D.; Iqbal, O.; Mosier, M.; Mitchell, R.; Hoppensteadt, D.; Bouchard, C.; Fareed, J.; Gamelli, R., International angiology : a journal of the International Union of Angiology
  • Endogenous pro-thrombotic biomarkers from the arm and leg may not have the same value Lattimer, C. R.; Kalodiki, E.; Geroulakos, G.; Hoppensteadt, D.; Fareed, J., Phlebology / Venous Forum of the Royal Society of Medicine
  • Fibrinolytic Dysregulation in Total Joint Arthroplasty Patients: Potential Clinical Implications Guler, N.; Burleson, A.; Syed, D.; Banos, A.; Hopkinson, W.; Hoppensteadt, D.; Rees, H.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Immunoenzymatic and Biochip Array Profiling of the Biomarkers of Inflammation and Hemostatic Activation Processes in ESRD Richards, J.; Bansal, V.; Iqbal, O.; Hoppensteadt, D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Inflammation and Hemostatic Activation may Contribute to Postsurgical Thrombosis in Patients With Bladder Cancer Abro, S.; Clark, M.; Barkan, G.; Hoppensteadt, D.; Fareed, J.; Wojick, E.; Quek, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Perioperative Factors and Their Effect on the Fibrinolytic System in Arthroplasty Patients Burleson, A.; Guler, N.; Banos, A.; Syed, D.; Wanderling, C.; Hoppensteadt, D.; Rees, H.; Fareed, J.; Hopkinson, W., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Anticoagulant and Antithrombotic Actions of AVE5026 an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin, Hoppensteadt, D. A.; Gray, A.; Jeske, W. P.; Walenga, J. M.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product Sadeghi, N.; Kahn, D.; Syed, D.; Iqbal, O.; Abro, S.; Eshraghi, R.; Hoppensteadt, D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Inflammatory and procoagulant cytokine levels during pregnancy as predictors of adverse obstetrical complications Dibble, S.; Andersen, A.; Lassen, M. R.; Cunanan, J.; Hoppensteadt, D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Pharmacological profile of sulodexide Hoppensteadt, D. A.; Fareed, J., International angiology : a journal of the International Union of Angiology
  • Prevalence of metabolic syndrome in patients with end stage renal disease and relevance of biomarkers Saluk, J.; Bansal, V.; Hoppensteadt, D.; Syed, D.; Abro, S.; Fareed, J., International angiology : a journal of the International Union of Angiology
  • Restoration of Normal Prothrombin Time/International Normalized Ratio With Fresh Frozen Plasma in Hypocoagulable Patients Only, A. J., Jr; DeChristopher, P. J.; Iqal, O.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Sustained release of tissue factor following thrombosis of lower limb trauma Walenga, J. M.; Kaiser, P. C.; Prechel, M. M.; Hoppensteadt, D.; Jeske, W. P.; Misselwitz, F.; Bacher, P.; Lassen, M. R.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin Hoppensteadt, D.; Tsuruta, K.; Cunanan, J.; Hirman, J.; Kaul, I.; Osawa, Y.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Vascular Endothelial Growth Factor: a potential diagnostic biomarker for major depression Clark-Raymond, A.; Meresh, E.; Hoppensteadt, D.; Fareed, J.; Sinacore, J.; Halaris, A., Journal of psychiatric research
  • Burns Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Combined modalities in surgical patients Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Comparative studies on branded enoxaparin and a US generic version of enoxaparin Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Cunanan, J.; Khan, H.; Escalante, V.; Fareed, J.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Cost-effectiveness of prevention and treatment of VTE Nicolaides, A.; Hull, R. D.; Fareed, J.; Cardiovascular Disease Educational and Research Trust; European Venous Forum; North American Thrombosis Forum; International Union of Angiology and Union Internationale du Phlebologie, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Critical care medical patients Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Diagnosis and anticoagulant treatment Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • General vascular, bariatric, and plastic surgical patients, Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Gynecology and obstetrics Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction Govindan, S.; Kuster, D. W.; Lin, B.; Kahn, D. J.; Jeske, W. P.; Walenga, J. M.; Leya, F.; Hoppensteadt, D.; Fareed, J.; Sadayappan, S., American journal of cardiovascular disease
  • Increased expression of secreted frizzled-related protein-1 and microtubule-associated protein light chain 3 in keratoconus Iqbal, O.; Fisher, G.; Vira, S.; Syed, D.; Sadeghi, N.; Freeman, D.; Campbell, E.; Sugar, J.; Feder, R.; Fareed, J.; Bouchard, C., Cornea
  • Inferior vena cava filters Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Introduction Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Key questions to be answered Nicolaides, A.; Hull, R. D.; Fareed, J.; Cardiovascular Disease Educational and Research Trust; European Venous Forum; North American Thrombosis Forum; International Union of Angiology and Union Internationale du Phlebologie, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Medical patients Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Metabolic differences of current thienopyridine antiplatelet agents Fareed, J.; Jeske, W.; Thethi, I., Expert opinion on drug metabolism & toxicology
  • Neurosurgery Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Orthopedic surgery and trauma Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Patients with cancer Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Periprocedural management of antithrombotic therapy and use of bridging anticoagulation Nicolaides, A.; Hull, R. D.; Fareed, J.; Cardiovascular Disease Educational and Research Trust; European Venous Forum; North American Thrombosis Forum; International Union of Angiology and Union Internationale du Phlebologie, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Prevention and treatment of venous thromboembolism: international consensus statement (guidelines according to scientific evidence) Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Prevention of postthrombotic syndrome Nicolaides, A.; Hull, R. D.; Fareed, J.; Cardiovascular Disease Educational and Research Trust; European Venous Forum; North American Thrombosis Forum; International Union of Angiology and Union Internationale du Phlebologie, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Progressive increase of inflammatory biomarkers in chronic kidney disease and end-stage renal disease Sharain, K.; Hoppensteadt, D.; Bansal, V.; Singh, A.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Superficial vein thrombosis Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Surgical thrombectomy Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • The problem and the need for prevention Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Thrombolytic therapy Nicolaides, A.; Hull, R. D.; Fareed, J.; Cardiovascular Disease Educational and Research Trust; European Venous Forum; North American Thrombosis Forum; International Union of Angiology and Union Internationale du Phlebologie, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Thrombophilia Nicolaides, A.; Hull, R. D.; Fareed, J.; Cardiovascular Disease Educational and Research Trust; European Venous Forum; North American Thrombosis Forum; International Union of Angiology and Union Internationale du Phlebologie, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran rivaroxaban, and apixaban: potential clinical implication, Sadeghi, N.; Kahn, D.; Jeske, W.; Hoppensteadt, D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Treatment for patients with cancer Nicolaides, A.; Hull, R. D.; Fareed, J.; Cardiovascular Disease Educational and Research Trust; European Venous Forum; North American Thrombosis Forum; International Union of Angiology and Union Internationale du Phlebologie, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Urologic surgery Nicolaides, A.; Hull, R. D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Variations in the circulating heparin levels during maintenance hemodialysis in patients with end-stage renal disease Kaneva, K.; Bansal, V.; Hoppensteadt, D.; Cunanan, J.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates. Jeske, W.; Litinas, E.; Khan, H.; Hoppensteadt, D.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Cross-reactivity of various thrombin products with anti-rabbit antibodies to bovine human, and recombinant thrombin., Sadeghi, N.; Zhu, H.; Setty, S. K.; Cunanan, J.; Hoppensteadt, D.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin. Gray, A.; Litinas, E.; Jeske, W.; Fareed, J.; Hoppensteadt, D., Clinical & Applied Thrombosis/Hemostasis
  • Ischemic stroke in the setting of chronic immune thrombocytopenia in an elderly patient--a therapeutic dilemma De La Pena, A.; Fareed, J.; Thethi, I.; Morales-Vidal, S.; Schneck, M. J.; Shafer, D., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Old versus new oral anticoagulants: focus on pharmacology Fareed, J.; Thethi, I.; Hoppensteadt, D., Annual Review of Pharmacology & Toxicology
  • Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins Walenga, J. M.; Jeske, W. P.; Escalante, V.; Hoppensteadt, D.; Fareed, J.; Bakhos, M., International angiology : a journal of the International Union of Angiology
  • A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Jeske, W. P.; Hoppensteadt, D.; Gray, A.; Walenga, J. M.; Cunanan, J.; Myers, L.; Fareed, J.; Bayol, A.; Rigal, H.; Viskov, C., Thrombosis research
  • A multicenter pilot study to estimate the prevalence of bovine and human coagulation antibodies in the general US population. Fareed, J.; Paterson, C. A.; Crean, S. M., Clinical & Applied Thrombosis/Hemostasis
  • An open label non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers., Gomes, M.; Ramacciotti, E.; Hoppensteadt, D.; Walenga, J. M.; Lewis, B.; Thethi, I.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Jeske, W. P.; Walenga, J. M.; Samama, M. M.; Hoppensteadt, D.; Mayuga, M.; Fareed, J., Blood Coagulation & Fibrinolysis
  • Review: contaminants in heparin: review of the literature molecular profiling, and clinical implications, Ramacciotti, E.; Clark, M.; Sadeghi, N.; Hoppensteadt, D.; Thethi, I.; Gomes, M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Upregulation of surrogate markers of inflammation and thrombogenesis in patients with ESRD: pathophysiologic and therapeutic implications. Nelson, K.; Thethi, I.; Cunanan, J.; Hoppensteadt, D.; Bajwa, R.; Fareed, J.; Bansal, V., Clinical & Applied Thrombosis/Hemostasis
  • A consensus conference on complex biologics and low molecular weight heparin Kalodiki, E.; Fareed, J.; Tapson, W. F.; Hoppensteadt, D. A.; Carter, C. A.; Sussman, I.; Parker, S.; Harenberg, J.; Hull, R.; Rao, G.; Lovinger, D. F.; Reid, L. D.; Kakkar, A.; Talarico, L.; Ofosu, F. A.; Bussey, H. I.; Fanikos, J.; Groce, J. B.; Skinner, N.; Ahluwalia, M.; Iqbal, O.; Jackson, C. M.; Jeske, W. P.; Ramacciotti, E.; Van Thiel, D.; Wahi, R.; Walenga, J., International Angiology
  • Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist Mousa, S. A.; Jeske, W. P.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Apixaban to prevent venous thromboembolism after knee replacement. Fareed, J.; Hull, R., Lancet
  • Coagulation profiling of random-source cats. McGeehan, E.; Wielgus, K.; Cera, L.; Azarafrooz, F.; Buesing, R.; Dubach, J.; Fareed, J., Journal of the American Association for Laboratory Animal Science: JAALAS
  • Comparative studies on the topical administration of mucopolysaccharide and heparin ointments in nonhuman primates. Hoppensteadt, D. A.; Neville, B.; Schultz, C.; Jeske, W.; Raake, W.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Contaminants in heparins: are all facts known? Fareed, J.; Hoppensteadt, D. A.; Ramacciotti, E.; Hull, R. D., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Cross-reactivity of rabbit anti-bovine prothrombin/thrombin IgGs with bovine factor V/Va-related antigens. He, Z.; Hoppensteadt, D.; Morris, M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Cross-reactivity of rabbit anti-bovine thrombin IgGs with human alpha-thrombin and a recombinant version of human thrombin (Recothrom) He, Z.; Hoppensteadt, D.; Cunanan, J.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor. Erez, O.; Romero, R.; Vaisbuch, E.; Kusanovic, J. P.; Mazaki-Tovi, S.; Chaiworapongsa, T.; Gotsch, F.; Fareed, J.; Hoppensteadt, D.; Gabor, T. N.; Yoon, B. H.; Edwin, S.; Dong, Z.; Espinoza, J.; Mazor, M.; Hassan, S. S., Journal of Maternal-Fetal & Neonatal Medicine
  • In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative Kuziej, J.; Litinas, E.; Hoppensteadt, D. A.; Liu, D.; Walenga, J. M.; Fareed, J.; Jeske, W., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Inflammatory biomarker profiling in elderly patients with acute hip fracture treated with heparins. Knesek, M. J.; Litinas, E.; Adiguzel, C.; Hopkinson, W.; Hoppensteadt, D.; Lassen, M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Leukocyte telomere length is associated with measures of subclinical atherosclerosis. Panayiotou, A. G.; Nicolaides, A. N.; Griffin, M.; Tyllis, T.; Georgiou, N.; Bond, D.; Martin, R. M.; Hoppensteadt, D.; Fareed, J.; Humphries, S. E., Atherosclerosis
  • P-selectin in major depression: preliminary findings with venlafaxine treatment Piletz, J. E.; Halaris, A.; Iqbal, O.; Hoppensteadt, D.; Fareed, J.; Zhu, H.; Sinacore, J.; DeVane, C. L., International Journal of Health Science
  • Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis. Genzen, J. R.; Fareed, J.; Hoppensteadt, D.; Kurup, V.; Barash, P.; Coady, M.; Wu, Y. Y., Transfusion
  • An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients Kannan, M.; Saxena, R.; Adiguzel, C.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Adiguzel, C.; Iqbal, O.; Hoppensteadt, D.; Jeske, W.; Cunanan, J.; Litinas, E.; He, Z.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Comparison of immunogenic potentials of bovine thrombin preparations. Zhu, H.; Hoppensteadt, D.; Adiguzel, C.; Bick, R. L.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. Cella, G.; Vianello, F.; Cozzi, F.; Marotta, H.; Tona, F.; Saggiorato, G.; Iqbal, O.; Fareed, J., Journal of Rheumatology
  • European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats. Adiguzel, C.; Iqbal, O.; Demir, M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Evidence of maternal platelet activation excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death., Erez, O.; Gotsch, F.; Mazaki-Tovi, S.; Vaisbuch, E.; Kusanovic, J. P.; Kim, C. J.; Chaiworapongsa, T.; Hoppensteadt, D.; Fareed, J.; Than, N. G.; Nhan-Chang, C. L.; Yeo, L.; Pacora, P.; Mazor, M.; Hassan, S. S.; Mittal, P.; Romero, R., Journal of Maternal-Fetal & Neonatal Medicine
  • Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin. Adiguzel, C.; Bansal, V.; Litinas, E.; Cunanan, J.; Iqbal, O.; Nelson, K.; Kannan, M.; Hoppensteadt, D.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin. Viskov, C.; Bouley, E.; Hubert, P.; Martinez, C.; Herman, F.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Nitric oxide branch of arginine metabolism in depression: effect of venlafaxine Piletz, J. E.; Halaris, A.; Iqbal, O.; Hoppensteadt, D.; Fareed, J.; Zhu, H.; Sinacore, J.; DeVane, C. L., International Journal of Health Science
  • Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Li, B.; Suwan, J.; Martin, J. G.; Zhang, F.; Zhang, Z.; Hoppensteadt, D.; Clark, M.; Fareed, J.; Linhardt, R. J., Biochemical pharmacology
  • Pro-inflammatory biomakers in depression: treatment with venlafaxine. Piletz, J. E.; Halaris, A.; Iqbal, O.; Hoppensteadt, D.; Fareed, J.; Zhu, H.; Sinacore, J.; Devane, C. L., World Journal of Biological Psychiatry
  • Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application. Zhu, H.; Hoppensteadt, D.; Wahi, R.; Cunanan, J.; Adiguzel, C.; Bick, R. L.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Relative purity of different bovine thrombin preparations. Zhu, H.; Hoppensteadt, D.; Iqbal, O.; Litinas, E.; Adiguzel, C.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Adiguzel, C.; Jeske, W. P.; Hoppensteadt, D.; Walenga, J. M.; Bansal, V.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity Echart, C. L.; Graziadio, B.; Somaini, S.; Ferro, L. I.; Richardson, P. G.; Fareed, J.; Iacobelli, M., Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • A link between a hemostatic disorder and preterm PROM: a role for tissue factor and tissue factor pathway inhibitor. Erez, O.; Espinoza, J.; Chaiworapongsa, T.; Gotsch, F.; Kusanovic, J. P.; Than, N. G.; Mazaki-Tovi, S.; Vaisbuch, E.; Papp, Z.; Yoon, B. H.; Han, Y. M.; Hoppensteadt, D.; Fareed, J.; Hassan, S. S.; Romero, R., Journal of Maternal-Fetal & Neonatal Medicine
  • A tribute to Professor Hans Klaus Breddin Fareed, J.; Walenga, J. M., Seminars in Thrombosis and Hemostasis
  • Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Fareed, J.; Jeske, W.; Fareed, D.; Clark, M.; Wahi, R.; Adiguzel, C.; Hoppensteadt, D., Clinical & Applied Thrombosis/Hemostasis
  • Argatroban in percutaneous coronary indications Iqbal, O.; Adiguzel, C.; Lewis, B. E.; Cunanan, J.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin Fareed, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Prechel, M.; Iqbal, O.; Adiguzel, C.; Clark, M.; Litinas, E.; cunanan, J.; Linhardt, R.; Harenberg, J., Seminars in thrombosis and hemostatis
  • Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed, J.; Iqbal, O.; Cunanan, J.; Demir, M.; Wahi, R.; Clarke, M.; Adiguzel, C.; Bick, R., International Angiology
  • Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. Hoppensteadt, D.; Fareed, J.; Klein, A. L.; Jasper, S. E.; Apperson-Hansen, C.; Lieber, E. A.; Katz, W. E.; Malouf, J. F.; Stoddard, M. F.; Pape, L. A., American Journal of Cardiology
  • Contaminant in the recalled unfractionated heparin preparations: where is the problem?. Hoppensteadt, D. A.; Wahi, R.; Adiguzel, C.; Iqbal, O.; Ramacciotti, E.; Bick, R. L.; Messmore, H. L.; Bansal, V.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Contaminants in heparins continue to be unfolded. Fareed, J.; Ahluwalia, M.; Wahi, R.; Ramaccioti, E.; Hoppensteadt, D.; Bick, R. L., International Angiology
  • Differentiating low-molecular-weight heparins based on chemical biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins, Jeske, W. P.; Walenga, J. M.; Hoppensteadt, D. A.; Vandenberg, C.; Brubaker, A.; Adiguzel, C.; Bakhos, M.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Dr. Eberhard F. Mammen remembered. A great clinician-scientist mentor, and friend., Fareed, J.; Walenga, J. M.; Hoppensteadt, D. A.; Bick, R. L.; Messmore, H. L., Seminars in Thrombosis and Hemostasis
  • Laboratory evaluation of the antiphospholipid syndrome Hoppensteadt, D. A.; Fabbrini, N.; Bick, R. L.; Messmore, H. L.; Adiguzel, C.; Fareed, J., Hematology - Oncology Clinics of North America
  • Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. Clark, M.; Hoppensteadt, D.; Walenga, J. M.; Myers, L.; Cunanan, J.; Jeske, W.; Adiguzel, C.; Iqbal, O.; Fareed, J., International Angiology
  • Potency Adjusted Generic Versions of Argatroban can be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays Adiguzel, C.; Iqbal, O.; Cunanan, J.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • Premature labor: a state of platelet activation?. Erez, O.; Romero, R.; Hoppensteadt, D.; Fareed, J.; Chaiworapongsa, T.; Kusanovic, J. P.; Mazaki-Tovi, S.; Gotsch, F.; Than, N. G.; Vaisbuch, E.; Kim, C. J.; Espinoza, J.; Mittal, P.; Hamill, N.; Nhan-Chang, C. L.; Mazor, M.; Hassan, S., Journal of perinatal medicine
  • Pyelonephritis during pregnancy: a cause for an acquired deficiency of protein Z. Nien, J. K.; Romero, R.; Hoppensteadt, D.; Erez, O.; Espinoza, J.; Soto, E.; Kusanovic, J. P.; Gotsch, F.; Kim, C. J.; Mittal, P.; Fareed, J.; Santolaya, J.; Chaiworapongsa, T.; Edwin, S.; Pineles, B.; Hassan, S., Journal of Maternal-Fetal & Neonatal Medicine
  • Survival of heparins oral anticoagulants, and aspirin after the year 2010, Fareed, J.; Hoppensteadt, D. A.; Fareed, D.; Demir, M.; Wahi, R.; Clarke, M.; Adiguzel, C.; Bick, R., Seminars in Thrombosis & Hemostasis
  • The anti-inflammatory effects of argatroban can be differentiated from other direct thrombin inhibitors: experimental and clinical observations. Hoppensteadt, D. A.; Jeske, W.; Walenga, J. M.; Bick, R. L.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • The future of anticoagulation Hoppensteadt, D. A.; Jeske, W.; Walenga, J. M.; Fareed, J., Seminars in Respiratory & Critical Care Medicine
  • Heparin oligosaccharides as potential therapeutic agents in senile dementia Ma, Q.; Cornelli, U.; Hanin, I.; Jeske, W. P.; Linhardt, R. J.; Walenga, J. M.; Fareed, J.; Lee, J. M., Current pharmaceutical design
  • In vitro heparan sulfate modulates the immune responses of normal and tumor-bearing mice. Rashid, R. M.; Lee, J. M.; Fareed, J.; Young, M. R., Immunological investigations
  • Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery. Demir, M.; Duran, E.; Yigitbasi, O.; Vural, O.; Kurum, T.; Yuksel, M.; Turgut, B.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Ma, Q.; Tobu, M.; Schultz, C.; Jeske, W.; Hoppensteadt, D. A.; Walenga, J. M.; Cornelli, U.; Lee, J.; Linhardt, R.; Hanin, I.; Fareed, J., Thrombosis research
  • Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Ravindranath, T. M.; Goto, M.; Iqbal, O.; Florian-Kujawski, M.; Hoppensteadt, D.; Hammadeh, R.; Sayeed, M. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Presence of asymmetric dimethylarginine gradients across high-grade lesions in patients with coronary artery disease. Joyal, D.; Leya, F.; Al Chekakie, M. O.; Arab, D.; Dieter, R. S.; Morshedi-Meibodi, A.; Lewis, B.; Steen, L.; Fareed, J.; Hoppenstead, D.; Akar, J. G., Coronary artery disease
  • Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate. Maddineni, J.; Hoppensteadt, D. A.; Cornelli, U.; Manoni, M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Why differentiate low molecular weight heparins for venous thromboembolism?. Fareed, J.; Walenga, J. M., Thrombosis Journal [Electronic Resource]
  • Clinical applications of bioinformatics genomics, and pharmacogenomics, Iqbal, O.; Fareed, J., Methods in Molecular Biology
  • In vivo heparan sulfate treatment alters the immune response of normal and LLC-bearing mice. Rashid, R. M.; Lee, J. M.; Fareed, J.; Young, M. R., Immunopharmacology & Immunotoxicology
  • Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis. Maddineni, J.; Jeske, W. P.; Baltasar, F.; Cornelli, U.; Manoni, M.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications Maddineni, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D. A.; Fareed, J.; Wahi, R.; Bick, R. L., Clinical & Applied Thrombosis/Hemostasis
  • Update on the clinical applications of argatroban. Fareed, J.; Jeske, W. P.; Hoppensteadt, D. A.; Walenga, J. M., Future Cardiology
  • Comparative tissue factor pathway inhibitor release potential of heparins. Tobu, M.; Ma, Q.; Iqbal, O.; Schultz, C.; Jeske, W.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Development of generic low molecular weight heparins: a perspective Fareed, J.; Leong, W.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Bick, R. L., Hematology - Oncology Clinics of North America
  • Short- and long-acting synthetic pentasaccharides as antithrombotic agents Walenga, J. M.; Jeske, W. P.; Fareed, J., Expert opinion on investigational drugs
  • Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. Iqbal, O.; Tobu, M.; Aziz, S.; Gerdisch, M.; Da Valle, M.; Demir, M.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Fareed, J., Journal of cardiac surgery
  • A survey of venous thrombosis models Jeske, W. P.; Iqbal, O.; Fareed, J.; Kaiser, B., Methods in Molecular Medicine
  • Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Tobu, M.; Iqbal, O.; Hoppensteadt, D.; Neville, B.; Messmore, H. L.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile Fareed, J.; Hoppensteadt, D.; Schultz, C.; Ma, Q.; Kujawski, M. F.; Neville, B.; Messmore, H., Current pharmaceutical design
  • Biomarker profiling of plasma from acute coronary syndrome patients. Application of ProteinChip Array analysis. Florian-Kujawski, M.; Hussain, W.; Chyna, B.; Kahn, S.; Hoppensteadt, D.; Leya, F.; Fareed, J., International Angiology
  • Blood levels of nitric oxide C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications., Fareed, D.; Iqbal, O.; Tobu, M.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis. Ahmad, S.; Untch, B.; Haas, S.; Hoppensteadt, D. A.; Misselwitz, F.; Messmore, H. L.; Walenga, J. M.; Fareed, J., Molecular & Cellular Biochemistry
  • Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications. Florian-Kujawski, M.; Hoppensteadt, D.; Maddineni, J.; Ziegler, H.; Fareed, J., International Angiology
  • Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis Fareed, J.; Ma, Q.; Florian, M.; Maddineni, J.; Iqbal, O.; Hoppensteadt, D. A.; Bick, R. L., Seminars in Thrombosis & Hemostasis
  • Differentiation of low-molecular-weight heparins: practical implications. Fareed, J.; Bick, R., Clinical & Applied Thrombosis/Hemostasis
  • Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncology. Hoppensteadt, D. A.; Fareed, J.; Bick, R. L., Seminars in Thrombosis & Hemostasis
  • Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Tobu, M.; Iqbal, O.; Fareed, D.; Chatha, M.; Hoppensteadt, D.; Bansal, V.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Factor Xa inhibitors Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J., Methods in Molecular Medicine
  • Generic low-molecular-weight heparins: some practical considerations Fareed, J.; Leong, W. L.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Wahi, R.; Bick, R. L., Seminars in Thrombosis & Hemostasis
  • Heparin to pentasaccharide and beyond: the end is not in sight Messmore, H. L.; Wehrmacher, W. H.; Coyne, E.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Laboratory analysis of blood samples from patients treated with tinzaparin. Hoppensteadt, D. A.; Willows, L.; Leitz, H.; Nicolaides, A.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan. Maddineni, J.; Ma, Q.; Hoppensteadt, D. A.; Demir, M.; Manoni, M.; Cornelli, U.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. Jeske, W.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Small-molecule direct antithrombins: argatroban Fareed, J.; Jeske, W. P., Bailliere's Best Practice in Clinical Haematology
  • Factor Xa inhibitors: today and beyond Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J., Current Opinion in Investigational Drugs
  • Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use. Tobu, M.; Iqbal, O.; Ma, Q.; Schultz, C.; Jeske, W.; Hoppensteadt, D.; Lewis, B.; Fareed, D.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Heparin low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation, Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Bick, R. L., Hematology - Oncology Clinics of North America
  • Influence of different anticoagulant agents on fibrinopeptide a generation. Tobu, M.; Iqbal, O.; Messmore, H. L.; Ma, Q.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Management of thrombotic and cardiovascular disorders in the new millenium Fareed, J.; Hoppensteadt, D. A.; Bick, R. L., Clinical & Applied Thrombosis/Hemostasis
  • Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice Fareed, J.; Hoppensteadt, D.; Walenga, J. M.; Iqbal, O.; Ma, Q.; Jeske, W.; Sheikh, T., Clinical pharmacokinetics
  • Pharmacodynamics and pharmacokinetics of C3 a heparin-derived oligosaccharide mixture, in non-human primates., Ma, Q.; Schultz, C.; Neville, B.; Jeske, W.; Hoppensteadt, D.; Cornelli, U.; Lee, J.; Lorens, S.; Hanin, I.; Fareed, J., Thrombosis research
  • Day-night variations in blood levels of nitric oxide T-TFPI, and E-selectin., Kanabrocki, E. L.; George, M.; Hermida, R. C.; Messmore, H. L.; Ryan, M. D.; Ayala, D. E.; Hoppensteadt, D. A.; Fareed, J.; Bremner, F. W.; Third, J. L.; Shirazi, P.; Nemchausky, B. A., Clinical & Applied Thrombosis/Hemostasis
  • Emerging anticoagulant and thrombolytic drugs Iqbal, O.; Aziz, S.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Bakhos, M.; Fareed, J., Expert opinion on emerging drugs
  • Circadian relationship of serum uric acid and nitric oxide. Kanabrocki, E. L.; Third, J. L.; Ryan, M. D.; Nemchausky, B. A.; Shirazi, P.; Scheving, L. E.; McCormick, J. B.; Hermida, R. C.; Bremner, W. F.; Hoppensteadt, D. A.; Fareed, J.; Olwin, J. H., JAMA

Pharmacology of drugs used in the treatment of thrombosis and bleeding disorders

My major research interests remain focused on the areas of the pathophysiology of thrombotic and cardiovascular disorders and their pharmacologic management. Thus my research interests are divided into the following six major topics: pathophysiologic characterization of thrombotic and cardiovascular agents, development of new antithrombotic drugs, pharmacologic differentiation of low molecular weight heparins, development of heparinomimetic drugs, molecular modeling of thrombogenesis using simulated systems, and development of animal models of thrombotic and ischemic disorders.